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Abstract 
Medical cannabis (MC) is gaining recognition as a treatment option in healthcare and yet, it still 
lags behind in the area of mental health.  This inquiry examines the lived experience of people 
aged 18 to 25, living with anxiety, with an objective of examining their attitude towards MC as a 
treatment option for anxiety.  The inquiry extends further to examine the participants 
understanding of MC and their concerns about accessing it is a treatment for anxiety.  A link to 
an electronic survey consisting of 22 questions was posted on social media.  The 135 responses 
received indicated that there is significant interest in MC as a treatment option for anxiety.  The 
greatest barriers experienced by participants were side effect concerns that related more directly 
to recreational cannabis (RC) and stigma related more directly to RC.  The results indicate that 
there is a lack of understanding and education regarding the differences between MC and RC   
Based on the results of this survey, it is recommended that the general public, including 
healthcare professionals, need extensive education on the possible benefits and risks of MC and 
how they differ from RC. 
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Introduction 
Medical cannabis (MC) is relatively new in terms of being a viable treatment option in 
medical interventions and is slowly gaining recognition.  However, while research into MC as a 
medical treatment option is increasing, research into MC as a treatment in mental health is still 
lagging behind other areas of healthcare.  There are large gaps in the literature regarding the use 
of MC in mental health treatment in general, and for anxiety treatment in particular (Andersen, 
2017).  To better understand the significance of this disparity, and the need for a research 
inquiry, a short literature review is appropriate. 
Literature Review  
In general, mental healthcare and treatment does not receive the priority that other areas 
of healthcare receive (Bailey & Smith, 2014). There is still stigma attached to mental health 
which affects individuals’ treatment options and access to treatment (Anderson, 2017).   While 
there are gaps in the literature for MC as a psychiatric treatment option, this situation is 
particularly critical in terms of anxiety treatment due to the sheer prevalence of anxiety 
disorders.  Anxiety and anxiety related disorders are the most prevalent mental heath issue in 
North America (Turna, Patterson, & Van Ameringen, 2017) with a many as one in four people 
being affected (Jurkus et al., 2016).   25% of those affected experience a severity of symptoms 
that greatly reduces their quality of life (Anderson, 2017).   Elevated rates of unemployment, 
relationship breakdowns, diminished sense of well-being, and elevated suicide risk are all 
associated with anxiety and anxiety related disorders (Blessing, Steenkamp, Manzanares, & 
Marmar, 2015).   Moreover, the age of onset is early even given the variance between different 
disorders.  Age of on onset can be as early as childhood and adolescence with the majority of 
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people experiencing anxiety onset before the age of 24 (Bandelow, Michaelis, & Wedekind, 
2017).  Anxiety treatment may be a lifelong concern for a significant number of people.  
While there is clearly a need for anxiety treatments, the current and most commonly used 
medical treatments for anxiety symptoms are cause for more concern.  Anti-depressants, 
including selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake 
inhibitor (SNRI), and benzodiazepines are the most prescribed treatments for anxiety and all  are 
associated with numerous side effects (Anderson, 2017, Bandelow et al., 2017, Turna et al., 
2017).  The treatment response rates associated with these treatment options are disappointing 
with 40-60% of patients continuing to experience impairing and residual symptoms (Turna et al., 
2017).  Individuals that experience low efficacy or significantly disabling side effects from these 
treatments are more likely to discontinue treatment or be labeled noncompliant (Turna et al., 
2017).   
   Clearly, there is a significant need for more options for anxiety treatment and yet 
research into MC as treatment option for anxiety still lags behind research in other areas of 
healthcare.  MC is a relatively new treatment option and a lack of education concerning the 
differences between MC and RC leads to stigma associated with RC, which was illegal until 
recently (Campbell, Phillips, & Manasco, 2017).  Much of the historical research on cannabis 
focused on RC, it being an illicit drug whose use resulted in negative consequences (Walsh et al., 
2017).  Furthermore, this research generally associated cannabis with risks to mental health, 
including psychosis and exacerbating anxiety symptoms (Turna et al., 2017).  Stigma and 
association of MC with RC’s psychoactive effects is even more prevalent in pediatric 
populations (Campbell et al., 2017) and psychiatric populations (Anderson, 2017).    
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Understanding the differences between MC and RC is fundamental to understanding the 
potential for treatment.  Tetrahydrocannabinol (THC) is the component of cannabis associated 
with psychoactive effects and RC (Blessing et al., 2015).   It is also associated with the risks of 
psychosis and worsening of anxiety symptoms.  Cannabidiol (CBD) is a phytocannabinoid 
constituent of cannabis and is not associated with psychoactive effects (Blessing et al., 2015, 
Calapai et al., 2019).  CBD is the component of cannabis that is sought out for medical purposes 
and is associated with antipsychotic, antidepressant and anxiolytic effects (Bonaccorso, S., 
Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F., 2019, Crippa, Guimarães, Campos, & 
Zuardi, 2018 ).  The anxiolytic effects may reduce anxiety symptoms and have been seen to be 
effective in both animal and human research (Lee, Bertoglio, Guimarães, & Stevenson, 2017). 
Research has indicated that increased levels of CBD in chronically consumed cannabis may be 
beneficial in preventing the undesirable effects of THC including the risk of psychosis (Blessing 
et al., 2015) and exacerbated anxiety (White, 2019).   Available research strongly indicates that 
CBD may be beneficial in the treatment of anxiety but that there is a need for further research 
(Calapai et al., 2019, Crippa et al., 2018, Mandolini et al., 2018). 
Rationale for Study 
.   The intent of this study is to examine the lived experience of youth aged 18-25 that 
identify as living with anxiety in an effort to better understand their knowledge, experience and 
concerns about anxiety treatments including MC.  This study considers the need for more 
comprehensive and informed treatment for anxiety and examines the multifaceted systemic 
factors that influence how individuals are educated about MC.  Such an examination can begin 
identifying areas in which the healthcare system needs to better respond to treatment needs and 
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expand the discussion surrounding MC as a viable treatment option.  This population was chosen 
because their age range is within the age of onset for most anxiety disorders.     
Theoretical Framework for Study 
 This study is a mixed method’s inquiry in which the participants’ lived experiences 
provide data that is both informative and instructive (Vagel, 2014, van Manen, 2016).  Founded 
within a phenomenological approach, the tool or instrument to access the participant’s data was 
Survey Monkey.  
Ethics 
This study was conducted in accordance with ethical review by the Research Ethics 
Board at Thompson Rivers University. 
.   Method 
This is a mixed methods study designed to address two research questions:  Are youth 
using or interested in using CBD as a treatment option for anxiety” and “what are the barriers to 
youth accessing MC as an option?”.   The survey was distributed electronically through 
SurveyMonkey and the survey link was active from September 6 to 27, 2019. 
Participant Recruitment 
1. A flyer with a link to the survey was distributed at the TRU Back to School BBQ from 
the TRU Wellness table (see appendix A). 
2. The researcher attended social work and cooperative education classes to inform students 
of the survey and distribute flyers.  
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3. An eposter with a link to the survey was distributed on TRU Wellness’s social media 
platforms: Facebook, Instagram and Twitter (see Appendix B). 
4. The link was emailed by research supervisors and course instructors to list serve groups 
and databases within their networks. 
5. A poster including the survey link was distributed on campus (see Appendix C) 
 Participants were able access the study electronically and participate in an environment of 
their choosing.  
Design and Procedure 
The first page of the survey included an explanation of the study and contact information 
for the researcher and supervisors (see Appendix D).  Also included at the beginning of the 
survey were definitions of CBD and anxiety, resources for anxiety support and consent (see 
Appendix E).   The survey itself consisted of six demographic questions, thirteen questions 
answered using a Likert scale and three open ended, short answer questions. Respondents that 
declined to participate or answered “no” to being within the prescribed age range of 18-25 were 
exited from the survey and thanked for their time and interest.  
           Upon completing the survey, participants were again given resources for support with 
coping with anxiety and they were invited to enter to win a gift card by sending an email with the 
word “options” to anxietytreatmentoptions@gmail.com  (see Appendix F).  This email address 
was set up specifically for this study and was only accessible by the researcher. Sixty-two 
responses had been received when the survey closed. The emails were assigned numbers from 1 
to 62 beginning with the first email received.  Research Randomizer (Urbaniak & Plouse, 2013), 
a random sampling program, was used to select the twenty winners.  The program was asked to 
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select one set of twenty random numbers, without repeats, from the set of sixty-two.  The email 
addresses corresponding to these numbers were electronically sent a $20.00 Starbucks gift card 
along with a note congratulating them on winning and thanking them for their participation.  
Analysis 
 Respondents that skipped question two,  “My age range is between 18 -25”, were 
excluded from the final analysis to ensure that participants were within the prescribed 
population.  This exclusion resulted in 135 participants.  
 Demographic questions two through six were forced answer questions and 
SurveyMonkey was used to analyse the data for the percentages of each response (see Tables 1 
to 5).   Demographic question seven was a short answer question regarding non-medical 
treatments.  Each response was tagged and analysed for percentages using Survey Monkey (see 
Table 6).  
 Quantitative questions 8 to 13 and 15 to 21 employed a Likert scale for the answers 
which included Strongly Agree, Agree, Neutral, Disagree and Strongly Disagree.  Excel was 
used to analyse the internal consistency of the quantitative survey questions.    A sample of 20 
responses to questions 8 to 13 and 15 to 21 was selected. The answers were translated to ordinal 
data starting with Strongly Agree being associated with 1 and finishing with Strongly Disagree 
being associated as 5.  This data was then analysed for Cronbach’s Alpha. Cronbach’s α = .4571.  
SurveyMonkey was used to analyse quantitative questions for percentages, median and mean 
(See Tables 7-12 and 14-20). 
 Qualitative questions 14, 21 and 22 required the participant to give a short answer to each 
question.  These answers were first coded using the tagging function in Survey Monkey to label 
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codes.  Each respondent’s answers were coded, with some having more than one code. Secondly, 
codes were examined for recurring themes.  Lastly, the percentage of respondents using 
particular codes was determined using SurveyMonkey (see Tables 13, 21 and 22). 
Results 
 The first notable result was that 77% of participants agreed or strongly agreed that they 
wanted more help with their anxiety indicating a desire for treatment and treatment options.  64% 
of participants agreed or strongly agreed that CBD may be used as medical.  19.70% of 
participants stated that they had no concerns about CBD as treatment for anxiety. These numbers 
indicate that a significant number of this sample are interested in CBD as treatment option for 
anxiety.    However, only 3.03% of participants disclosed that they have used CBD.  While there 
would seem to be interest in CBD as treatment option, the significant themes in the qualitative 
answers begin to illuminate the barriers to accessing it as a treatment option.  
  Side effects and stigma were the two most significant themes associated with the answers 
to question 23 “My concerns for using CBD as a treatment for anxiety include”.  While most 
often the response was simply side effect or stigma, many participants listed specific concerns in 
these areas.  Side effects were the most prevalent concern.  Some of the side effects listed 
included:  triggering schizophrenia, lack of motivation and being high.  What is most interesting 
about these results is that the specific side effects list strongly correlates with RC and THC and 
not MC and CBD.  The second most prevalent concern was stigma.  Specific stigma concerns 
listed included:  family, the workplace as well CBD not being recognized as a legitimate 
treatment or that inquiring about CBD with a health professional would lead to being labeled as 
“drug seeking”.    77% of participants stated that they were not receiving medical treatment for 
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anxiety.    Lastly, participants that agreed or strongly agreed that they considered CBD as a viable 
treatment for anxiety were asked to identify where they had learned this information.   28.33% 
stated friends and 20% identified personal experience.  Only 8.33% identified a healthcare 
professional as their source of information. 
Discussion 
 This study was a mixed methods survey, distributed electronically, examining whether 
youth between the ages of 18 to 25, who identify as living with anxiety are interested in anxiety 
treatment options, including MC.  It also examined, from the participants’ lived experience, what 
may be preventing them from considering or accessing MC as a treatment option.  The youth in 
this sample were interested in treatment options and a significant number of them considered MC 
a viable treatment option.  However, lack of education between the difference between MC and 
RC, and the stigma attached RC are making this treatment option inaccessible. 
The most notable themes participants disclosed in terms of their concerns about CBD as 
an anxiety treatment option were side effects and stigma. These themes illuminated a lack of 
understanding between side effects attributable to RC and not to CBD and indicate that there is a 
large gap in the public’s education about the difference between MC and RC.    The concerns 
over stigma, indicate a lack of knowledge about MC amongst not only the public but amongst 
healthcare professionals as well.  The low percentage of participants receiving any medical 
treatment for their anxiety may be indicative of stigma associated with seeking mental health 
treatment.  It’s likely that the stigma attached to mental health issues and treatment intersects 
with the stigma associated with RC and creates a larger barrier to accessing MC as a treatment 
for anxiety.  From a practical standpoint, the lack of education and misinformation regarding MC 
is preventing individuals from accessing a treatment option that may be more beneficial to them 
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than the most common options. These results support the need for more extensive education 
about MC within the general public, including healthcare professionals and agencies supporting 
individuals with mental health issues.   Such a step would support individuals to be able to make 
informed treatment decisions.   Future research would benefit from longer, in person interviews 
or focus groups that would enable more discussion regarding participants experiences accessing 
healthcare and treatment options for anxiety and allow for a deeper examination which would 
better inform methods for education and eradicating barriers. 
Limitations 
The internal consistency of the quantitative questions on the survey was low with 
Cronbach’s α = .4571. Another limitation to this study is that it is not possible to identify 
geographic locations of the participants and it is not able to identify if participant’s in different 
regions had different experiences.  This study was primarily advertised on a university campus 
and the survey link was shared using the university’s social media platforms.  It is possible many 
of the participants were university students which is not necessarily representative of a larger, 
general population.  Lastly, a larger sample may have resulted in more accurate means and 
helped identify any outliers within the raw data. 
Partnerships 
The TRU Wellness Centre agreed to be a research partner in this study.  It is in their best interest 
to learn more about the prevalence of youth living with anxiety on campus so that they are better 
able to respond with options for education, support and possible referrals.  Dr. Cindy James, 
Senior Assessment Centre Coordinator Chair, Counselling, Academic Support & Assessment, 
provided a letter support which was submitted to the TRU Research Ethics Board.  TRU 
Wellness assisted with distribution and advertising of the study.   
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Table 2.   
 









Question 4: I have lived with anxiety for: 
Response % 
0-6 month 15.04 
6 – 12 months 15.04 
1 - 3 years 18.05 





















Question 7:  I use the following alternative (non-medical) treatments for coping with anxiety 
(for example:  meditation, breathing exercise, yoga, etc).  
Coded Responses % 
Alcohol/cigarettes                   4.08 
Aromatherapy                   1.02   
Avoiding social interaction                   2.04 
Breathing exercises                                               45.92 
CBD                   5.10 
CBT or Exposure therapy                                         2.04 
Crafts                   1.02 
Exercise                 33.67 
Focussing on school                                                  1.02 
Grounding techniques                                              2.04 
Journaling                   4.08 
Marijuana                   4.08 
Meditation                    23.47 
Mindfulness                     2.04 
Music                      3.06 
None                                    1.02 
Pets                        1.02 
Planning ahead                   1.02 
Sleep                      3.06 
Social Connections                   8.16 
Spirituality                     1.02 





Question 8:  My experiences discussing my anxiety with doctors/nurses have been positive: 
Response % Mdn M 
     3       2.68 
Strongly Agree  5.26   
Agree 40.35   
Neutral 37.72   
Disagree 14.01   
Strongly Disagree  1.75   
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Table 8  
 
Question 9: My experiences discussing medication options with doctors/nurses have been 
negative. 
Response % Mdn M 
     3       3.31 
Strongly Agree  2.65   
Agree 12.39   
Neutral 43.36   
Disagree 34.51   





Question 10: My experiences discussing my anxiety with my parents/guardians have been 
positive. 
Response % Mdn M 
      
     2     2.66 
Strongly Agree           17.24   
Agree           36.21   
Neutral           17.24   
Disagree           21.55   





Question 11:  My experiences discussing medication with my parents/guardians have been 
negative: 
Response % Mdn M 
 
     3     3.3 
Strongly Agree  9.57   
Agree 18.26   
Neutral 26.96   
Disagree 23.48   
Strongly Disagree 21.74   
 




Question 12:  I want more help with my anxiety. 




     2    1.89 
Strongly Agree          38.79   
Agree          38.79   
Neutral          18.10   
Disagree            3.45   




Question 13:  CBD may be used as a medical option for anxiety 




     2     2.23 
Strongly Agree          18.97   
Agree          45.69   
Neutral          25.86   
Disagree            5.17   




Question 14: If you answered “strongly agree” or “agree” to question 13, where you hear 
this information? 
Coded Responses % 
Cannabis store                                          3.33 
Don’t recall                                              1.67 
Everywhere    1.67 
Family       8.33 
Friends 28.33 
Healthcare professional                           8.33 
Media/advertising                                    5.00 
Online 16.67 
Personal experience                              20.00 
Research   18.83 
Word of mouth                                         6.00 
 




Question 15: In general, I am comfortable talking about CBD with my doctor/nurse. 




     3     2.70 
Strongly Agree  7.02   
Agree 40.35   
Neutral 28.95   
Disagree 22.81   




Question 16:  In general, I am comfortable talking about CBD with my parents/guardians 




     3      2.8 
Strongly Agree      20.18    
Agree      26.32   
Neutral      19.30   
Disagree      21.93   




Question 17:  I would consider discussing CBD as an option for my anxiety                              







    2    2.37 
Strongly Agree 20.18   
Agree 45.61   
Neutral 15.79   
Disagree 14.04   
Strongly Disagree  4.39   
 




Question 18: I would consider discussing CBD as an option for my anxiety with my 
parents/guardians. 




     3    2.83 
Strongly Agree            13.27   
Agree            36.28   
Neutral            17.70   
Disagree            19.47   




Question 19: I am able to discuss my anxiety with my friends. 




      2     2.25 
Strongly Agree           26.32   
Agree           40.35   
Neutral           21.93   
Disagree             5.26   
Strongly Disagree             6.14   
 
 
Table 19  
  
Question 20:  I talk about CBD with my friends 




     3    2.72 
Strongly Agree           13.91   
Agree           33.04   
Neutral           28.70   
Disagree           15.65   
Strongly Disagree             8.70   
 




Question 21:  I am easily able to find information regarding treatment for my anxiety. 




      3    2.76 
Strongly Agree           8.70   
Agree         35.65   
Neutral         35.65   
Disagree         11.30   
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Table 21 
Question 22: My concerns for treatments for anxiety include:  
Coded Response % 
Accessibility                                  4.35 
Affordability                                  5.80 
Effectiveness                                 14.49   
Fear incorrect treatment                                  1.45 
Fear of dependency                                  2.90 
Fear of misdiagnosis                                  2.90 
Focussing on anxiety worsens it                                  1.45                            
Hesitancy w/ healthcare professionals                                  8.70 
Ineffective treatment plans                                  4.35 
Interaction with other medications                                  1.45 
Lack of knowledge                                                                   1.45 
Long term dependence on medication                                     1.45 
No concerns                                                                             8.70 
Not being believed                                                                   8.70 
Prefer natural treatments                                                         5.80 
Prefer not to take medication                                                 5.80 
S/E side effects                                                                     18.84 
S/E increased anxiety                                                             1.45 
S/E of current medications                                                     1.45 
S/E flat affect                                                                          2.90 
S/E increased mania                                                                1.45 
S/E increased suicidal ideation                                                1.45 
S/E lowers libido                                                                     1.45 
S/E no motivation                                                                    2.90 
S/E of previous medication                                                     1.45 
S/E weight gain                                                                       1.45 
Stigma                                                                                  11.59 
Stigma – mental health                                                            4.35 
Major themes:  Side effect concerns, stigma concerns, hesitancy with healthcare professionals, 
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Table 22 
Question 23: My concerns for CBD as a treatment for anxiety include:   
Coded responses % 
Accessibility                                                       6.06 
Accessibility – CBD                                    1.52 
Accessibility – prescription                                     1.52 
Addiction concerns                                  3.03 
Associate CBD and marijuana                                    3.03 
Concerns about dependency                                     6.06 
Concerns about correct dosing                                 1.52 
Concerns about effectiveness                                  6.06 
Efficacy of treatment                                 1.52 
Expense                                 7.58 
Lack of knowledge                                 7.58 
No concerns                               19.70 
No concerns – have used                                 3.03 
Not applicable                                 3.03 
Not enough research                               10.61 
Possible side effects (S/E)                               15.15 
Prefer nonmedical treatment                                 4.55 
S/E triggers schizophrenia                                 1.52 
S/E being high                                 3.03 
S/E depression                                 1.52 
S/E lack of motivation/focus                                 1.52 
S/E long term side effects                                 1.52 
S/E similar to marijuana                                 3.03 
S/E similar to vaping                                 1.52 
S/E sleepiness                                 3.03 
Stigma                                10.61 
Stigma – family                                  3.03 
Stigma – CBD not seen as legitimate                                   1.52 
Stigma – drug seeking                                  1.52 
Stigma – workplace                                  3.03 
Too much intervention                                  1.52 
Traveling with CBD                                  1.52 
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Appendix A 





Are you between 18 and 25? 
Do you live with anxiety? 
 
If you answered YES to both of these questions, 
please take 10 minutes to complete a survey 
and share your experiences anonymously. 
 
You will have a chance to  
enter to win 1 of 20, 
 $20 Starbuck gift certificates 
 




Thank you for supporting 
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Appendix B 
Post shared on TRU Wellness’s Facebook, Twitter and Instagram platforms. 
 
Are you between 18 and 25? Do you live with anxiety? 
In 10 minutes, you can anonymously share your experience 
by completing this survey and enter for a chance to 
win one of twenty $20 Starbucks gift cards. Closes this Friday, September 27! 
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Appendix C 
Poster distributed on TRU campus 
 
Are you between 18 and 25? 
Do you live with anxiety? 
 
If you answered YES to both of these questions, please 
share your experience and take 5 minutes to                                                          
anonymously complete this survey. 
 
You will have a chance to enter to win 1 of 20, 
$20 Starbuck gift cards. 
Find the survey at:    
https://www.surveymonkey.ca/r/5ZRSXV9 
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Appendix D 
Introduction to Survey and researcher contact information 
Principle investigator:   
Lanette LeWarne- TRU, Bachelor of Social Work Student 
Faculty Supervisors: 
Dr. Nan Stevens  
Assistant Professor, School of Education and Social Work, TRU 
Dr. Florriann Fehr  
Assistant Professor, School of Nursing, TRU 
 
Purpose of Study 
This study aims to learn more about youth experiencing anxiety and how youth view 
treatment options, such as counselling, prescribed medication, and medical 
cannabis.  Additionally, the goal of the study is to learn about treatment options that 
youth choose to access.  You may respond to a social media "call out".  In order to 
be eligible, you must self-identify as a person living with or experiencing anxiety (you 
may have a formal diagnosis).  For the purposes of this study, youth is defined as 
18-25 years old. 
 
If you agree to join this study, you will be asked to complete a 15 question survey 
that has questions concerning your awareness of and experiences with treatment 
options for individuals living with anxiety.  The survey is done electronically, using 
Survey Monkey, which ensures that responses will be confidential, as the researcher 
cannot connect the answers to an individual.  You do not have to join this study.  If 
you do choose to participate, you are free to change your mind and withdraw at any 
time.  The survey results will be used in conference presentations, journal articles 
and/or teaching sessions.  At any time, you may ask for the results of this 
study.  Once you complete the survey, you can enter your email into a 
draw.   Twenty participants will receive a $20 Starbucks gift card. 
 
If you have any questions about this study, please feel free to contact: 
Dr. Nan Stevens      Telephone:  250-852-7158      
                                 Email:  Nstevens@tru.ca 
 
Lanette LeWarne     Telephone:  250:682:4233      
                                 Email:  lewarnel16@mytru.ca 
 
Dr. Airini:                  Dean of Education and Social Work      
                                 Email:  Airini@tru.ca 
Research Ethics Chair contact information:   
                                 TRU-REB@tru.ca or 250-828-5000 
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Appendix E 
Definitions for the survey, resources for anxiety support and consent 
Definitions for the Survey: 
 
Anxiety:  Disruptive feelings of fear, worry or nervousness that can cause sweating, 
increased heart rate, tension or stomach aches.  They may feel a sense of "being on 
edge" even there is no danger present.  Anxiety may feel different between people. 
 
Cannabidiol (CBD):  This is the non-active (a person does not get high from 
CBD)  part of the marijuana plant that can be used for medical purposed.  For the 
purposes of this survey, we are focussing on the non-active aspect of medical 
cannabis (CBD). 
 
If you are triggered by the content of the questions and/or how the questions are 
worded, you may withdraw at any time.  Please access TRU counselling services on 
campus at      250-828-5471.  If you are not a TRU student, and you are triggered, 
you may withdraw at anytime.  Please seek counselling with a mental health service 
provider in your community.  Additionally, Anxiety Canada 
(www.anxietycanada.com) has a 24-hour phone line (604-620-0744) for support 
 
1.  Would you like to participate in this survey? 
   ○Yes, I would like to participate in this research study      













ANXIETY TREATMENT OPTIONS INCLUDING MEDICAL CANNABIS                       30 
 
Appendix F 
Resources for anxiety support and instructions for gift card contest 
If you have felt triggered by answering these questions, please seek support from a mental 
health service provider in your community.  TRU students can access on campus 
support through TRU Wellness located in Old Main.  Additionally, Anxiety Canada 
(www.anxietycanada.com) has a 24-hour phone line (604-620-0744) for support. 
 
Email the word "OPTIONS" to anxietytreatmentsurvey@gmail.com for your chance 
to win one of twenty $20 Starbucks gift cards.  Winners will have their gift card sent 
to them electronically. 
 
THANK YOU FOR TAKING THIS SURVEY! 
 
 
